Ute Hochgeschwender

Luminopsins integrate opto- and chemogenetics by using physical and biological light sources for opsin activation.

Combined Optogenetic and Chemogenetic Control of Neurons.

Cre-dependent DREADD (Designer Receptors Exclusively Activated by Designer Drugs) mice.

Bioluminescence imaging in live cells and animals.

SDF-1 overexpression by mesenchymal stem cells enhances GAP-43-positive axonal growth following spinal cord injury.

Novel luciferase-opsin combinations for improved luminopsins.

Effects of Passage Number and Differentiation Protocol on the Generation of Dopaminergic Neurons from Rat Bone Marrow-Derived Mesenchymal Stem Cells.

Bioluminescence-driven optogenetic activation of transplanted neural precursor cells improves motor deficits in a Parkinson's disease mouse model.

Neural Stem Cells Derived Directly from Adipose Tissue.

Altered Behavior in Mice Socially Isolated During Adolescence Corresponds With Immature Dendritic Spine Morphology and Impaired Plasticity in the Prefrontal Cortex.

Defining parameters of specificity for bioluminescent optogenetic activation of neurons using in vitro multi electrode arrays (MEA).

Step-function luminopsins for bimodal prolonged neuromodulation.

Intra-islet glucagon signaling is critical for maintaining glucose homeostasis.

Applications of 3D printing in small animal magnetic resonance imaging.

The BioLuminescent-OptoGenetic in vivo response to coelenterazine is proportional, sensitive, and specific in neocortex.

TBR-760, a Dopamine-Somatostatin Compound, Arrests Growth of Aggressive Nonfunctioning Pituitary Adenomas in Mice.

Selective postnatal excitation of neocortical pyramidal neurons results in distinctive behavioral and circuit deficits in adulthood.

Bioluminescent optogenetic (BL-OG) activation of neurons during mouse postnatal brain development.